Abstracts tagged "ANA"

Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting
Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic
Aparna Das, Rajarajan Panneerselvan, Annum Faisal, Jubran Rind and Rima Shah, Internal medicine, Michigan state university, grand rapids, MI
Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…
Abstract Number: 1683 • 2018 ACR/ARHP Annual Meeting
Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer
Mark Wener¹ and Mark H. Wener², ¹Division of Rheumatology, Department of Laboratory Medicine, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Titers of HEp-2 ANAs vary between laboratories, with many contributing factors. We sought to systematically determine the contribution of different ANA kit manufacturers to…
Abstract Number: 2107 • 2018 ACR/ARHP Annual Meeting
Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs
Nick Huang¹, Zhi-Wei Lai¹, Gourav Choudhary², Thomas Winans³, Ryan Kelly⁴, Katalin Banki⁵, Laurence Morel⁶ and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ³SUNY Upstate Medical University, Syracuse, NY, ⁴SUNY, Syracuse, NY, ⁵Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ⁶Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that is characterized by the production of autoantibodies against nuclear antigens (ANA) and phospholipids…
Abstract Number: 2125 • 2018 ACR/ARHP Annual Meeting
Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach
Vivian Kawai¹, Jonathan Mosley², QiPing Feng¹, Wei-Qi Wei³, Daniel Carranza Leon², Cecilia P. Chung⁴, Andrea Ihegword² and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Medicine, Vanderbilt University Medical Center, Nashville, TN, ³Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: ANAs are almost always present in systemic lupus erythematosus (SLE), but they are also present in ~12-20% of the population. A positive ANA (ANA+)…
Abstract Number: 2712 • 2018 ACR/ARHP Annual Meeting
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
Mayce Haj-Ali¹, Derek Jones², Sean McNish³, Sarah Stupp³, Marissa Mangini³ and Victoria Shanmugam⁴, ¹Department of Medicince, The George Washington University School of Medicine and Health Sciences, Washington, DC, ²The George Washington University, Washington, DC, ³The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by inflammation, fibrosis, and vasculopathy. Historical data indicates approximately 90% of patients with SSc test positive…
Abstract Number: 2578 • 2017 ACR/ARHP Annual Meeting
RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE
Gourav Choudhary¹, Nick Huang², Thomas Winans³, Ryan Kelly⁴, Sarah Blair³, Miguel Beckford³ and Andras Perl², ¹Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY Upstate Medical University, Syracuse, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease characterized by circulating antinuclear autoantibodies and dysfunction of B cells, T cells, and dendritic…
Abstract Number: 43 • 2017 ACR/ARHP Annual Meeting
Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE
Daniele Mauro¹, Victoria Tsang², Isabelle A. Clayton-Lucey³, Sara Pagani², Farah Alam², Elena Pontarini², Alessandra Nerviani², Angela Pakozdi⁴, Andrea Cove-Smith⁴, Ravindra Rajakariar⁴, Debasish Pyne⁴, Timothy J Vyse⁵, Costantino Pitzalis² and Myles J. Lewis^4,6, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom, ⁴Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, ⁵Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, London, United Kingdom, ⁶Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: A single risk haplotype spanning UBE2L3 is strongly associated with SLE and multiple autoimmune diseases. The E2 ubiquitin-conjugating enzyme UBE2L3 regulates TNFα and CD40…
Abstract Number: 198 • 2017 ACR/ARHP Annual Meeting
The Impact of Electronic Consults (E-Consults) on Positive ANA Referrals in a Veteran Population
Veena Patel^1,2, Diana Stewart^2,3 and Molly Horstman^1,2,4, ¹Internal Medicine, Baylor College of Medicine, Houston, TX, ²Internal Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, ³Internal Medicine and Pediatrics, Baylor College of Medicine, Houston, TX, ⁴Center for Innovations in Quality, Effectiveness and Safety (iQUEST), Houston, TX
Background/Purpose: Referrals to rheumatology for positive ANA in the absence of clinical signs and symptoms is a common practice, which may lead to unnecessary resource…
Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting
Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Katy A. Lloyd¹, Peter Sahlström², Johanna Steen¹, Philip J. Titcombe^3,4, Diana Zhou¹, Christina Lundqvist⁵, Olov Ekwall^6,7, Jimmy Ytterberg¹, Johan Rönnelid⁸, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁹, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ⁵Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁶Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of Gothenburg, Göteborg, Sweden, ⁷Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁸Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁹Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…
Abstract Number: 559 • 2017 ACR/ARHP Annual Meeting
Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome
Astrid Rasmussen¹, Kiely Grundahl², Lida Radfar³, C. Erick Kaufman⁴, David M. Lewis⁵, Barbara M. Segal⁶, Nelson L. Rhodus⁷, Harini Bagavant¹, Umesh Deshmukh⁸, Christopher J Lessard⁸, R. Hal Scofield¹ and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁴College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Oral Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁶Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ⁷Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The research classification and clinical diagnosis of SjšgrenÕs syndrome (SS) relies heavily on the detection of autoantibodies against Ro/SSA and La/SSB, particularly in the…
Abstract Number: 673 • 2017 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Distinguish Systemic Lupus Erythematosus from Other Diseases Among Patients with High Antinuclear Antibody Titers and Normal Complement
Daniel J. Wallace¹, Elena Massarotti², Rosalind Ramsey-Goldman³, Christopher E. Collins⁴, Anca Askanase⁵, Jill P. Buyon⁶, Richard Furie⁷, Sonali Narain⁷, Amit Saxena⁸, Kenneth C. Kalunian⁹, Cristina Arriens¹⁰, Chaim Putterman¹¹, John Conklin¹², Roberta Alexander¹², Claudia Ibarra¹², Tyler O'Malley¹³, Tarun Chandra¹⁴, Joseph Ahearn¹⁵, Susan Manzi¹⁶, Arthur Weinstein¹⁷ and Thierry Dervieux¹², ¹Cedars-Sinai Medical Center, UCLA, Los Angeles, CA, ²Brigham and Women's Hospital, Boston, MA, ³FSM, Northwestern University, Chicago, IL, ⁴Rheumatology, MedStar Washington Hospital Center, Washington, DC, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Rheumatology, NYU Langone Medical Center, New York, NY, ⁷Northwell Health, Great Neck, NY, ⁸NYU Langone Medical Center, New York, NY, ⁹Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ¹⁰Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹²Exagen Diagnostics, Inc., Vista, CA, ¹³Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁴EmpiriQA LLC, Long Grove, IL, ¹⁵Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁶Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC
Background/Purpose: Patients are often referred to the rheumatologist because of elevated anti-nuclear antibody (ANA) titers. We sought to evaluate the association of cell bound complement…
Abstract Number: 700 • 2017 ACR/ARHP Annual Meeting
Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Stanley J. Naides¹, Jonathan Genzen², Gyorgy Abel³, Christine Bashleben⁴ and Mohammad Qasim Ansari⁵, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²ARUP Laboratories Inc, Salt Lake City, UT, ³Department of Pathology and Laboratory Medicine, Lahey Clinic Burlington, Burlington, VT, ⁴College of American Pathologists, Northfield, IL, ⁵Department of Pathology and Laboratory Medicine, Louis Stokes VAMC, Cleveland, OH
Background/Purpose: A 2010 American College of Rheumatology position paper designated indirect immunofluorescence assay (IFA) on HEp-2 cells the “gold standard” for ANA testing and that…
Abstract Number: 1097 • 2017 ACR/ARHP Annual Meeting
Investigating Opportunities for Cost Conscious Care: A Review of Physician Practice in Ordering Anti-Nuclear Antibody Testing at an Academic Community Hospital
Hrudya Abraham, Jorge Espinal and Sindhu Joseph, Internal Medicine, MacNeal Hospital, Berwyn, IL
Background/Purpose: More than 94,000 ANA tests are performed each year resulting in an estimated cost of 2.24 million dollars annually. The American College of Rheumatology…
Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
David Pisetsky¹, Dana Thompson¹, Joseph Wajdula², Annette Diehl² and Sudhakar Sridharan³, ¹Duke University Medical Center and Durham VAMC, Durham, NC, ²Global Product Development, Pfizer Inc, Collegeville, PA, ³PPD Inc, Rockville, MD
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…
Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Luis E C Andrade¹, Jan Damoiseaux², Minoru Satoh³, Edward K.L. Chan⁴, Mônica Prado⁵, Henrique Mariz⁶, Renan Agustinelli⁷ and Alessandra Dellavance⁸, ¹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Dept of Oral Biology, University of Florida, Gainesville, FL, ⁵Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ⁷Rheumatology Division, Escola Paulista de Medicina, São Paulo, Brazil, ⁸Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].